Orum Therapeutics is a private biotech developing next-generation TPD technologies. Orum's novel and proprietary next generation targeted protein degradation (TPD) platform, TPD2 AnDC (Antibody neoDegrader Conjugate), enables tumor-specific targeting for multiple indications. Orum was founded in 2016 and has labs and offices operating out of Daejeon, South Korea, and Cambridge, MA, US.